Granted Patent
B2
US 12,740,992 · App. 18/006,121 · Granted Sep 22, 2026
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
Assignee:
Jazz Pharmaceuticals Research UK Limited
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients diagnosed with PCDH19 Epilepsy. In a further embodiment the types of seizures include tonic-clonic seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.
Claims (13)
1 . A method of treating seizures associated with a PCDH19 mutation in a patient in need thereof comprising administering a cannabidiol (CBD) drug substance to the patient in need thereof, wherein the CBD drug substance comprises greater than 95% (w/w) CBD and not more than 0.15% (w/w) tetrahydrocannabinol (THC).
2 . The method of claim 1 , wherein the seizures associated with a PCDH19 mutation are tonic-clonic seizures.
3 . The method of claim 1 , wherein the CBD drug substance comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) other cannabinoids, wherein the less than or equal to 2% (w/w) other cannabinoids comprise the cannabinoids tetrahydrocannabinol (THC); cannabidiol-C1 (CBD-C1); cannabidivarin (CBDV); and cannabidiol-C4 (CBD-C4), and wherein the THC is present as a mixture of trans-THC and cis-THC.
4 . The method of claim 1 , comprising administering the CBD drug substance in combination with one or more concomitant anti-epileptic drugs (AED).
5 . The method of claim 4 , wherein the one or more AED is selected from the group consisting of: levetiracetam, clobazam, topiramate, gabapentin and phenytoin.
6 . The method of claim 1 , wherein the CBD is present is isolated from cannabis plant material.
7 . The method of claim 1 , wherein at least a portion of at least one of the cannabinoids present in the CBD drug substance is isolated from cannabis plant material.
8 . The method of claim 1 , wherein the CBD is present as a synthetic drug substance.
9 . The method of claim 8 , wherein at least a portion of at least one of the cannabinoids present in the CBD drug substance is prepared synthetically.
10 . The method of claim 1 , wherein the dose of CBD is greater than 5 mg/kg/day.
11 . The method of claim 1 , wherein the dose of CBD is 20 mg/kg/day.
12 . The method of claim 1 , wherein the dose of CBD is 25 mg/kg/day.
13 . The method of claim 1 , wherein the dose of CBD is 50 mg/kg/day.
Assignments (4)
CHANGE OF NAME
Recorded May 19, 2025
From: GW RESEARCH LIMITED
To: JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Reel/Frame 071152/0822 →
SECURITY AGREEMENT
Recorded Jul 26, 2024
From: CAVION, INC.; CELATOR PHARMACEUTICALS, INC.; GW PHARMA LIMITED; JAZZ PHARMACEUTICALS, INC.; JAZZ PHARMACEUTICALS IRELAND LIMITED; JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (F/K/A GW RESEARCH LIMITED)
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 068173/0155 →
CORRECTIVE ASSIGNMENT TO CORRECT THE COUNTRY IS "UNTIED KINGDOM" PREVIOUSLY RECORDED AT REEL: 064583 FRAME: 0069. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT.
Recorded Aug 25, 2023
From: CHECKETTS, DANIEL ADAM; CRAIG, KEVIN JAMES
To: GW RESEARCH LIMITED
Reel/Frame 064719/0529 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 14, 2023
From: CHECKETTS, DANIEL ADAM; CRAIG, KEVIN JAMES
To: GW RESEARCH LIMITED
Reel/Frame 064583/0069 →
Priority Claims (1)
GB 2011127
· Jul 20, 2020
· national
Continuity (1)
References Cited (260)
US 8632825B2
· Velasco Diez et al.
· 2014
[cited by applicant]
US 8790719B2
· Parolaro et al.
· 2014
[cited by applicant]
US 9017737B2
· Kikuchi et al.
· 2015
[cited by applicant]
US 9125859B2
· Whalley et al.
· 2015
[cited by applicant]
US 9474726B2
· Guy et al.
· 2016
[cited by applicant]
US 9675654B2
· Parolaro et al.
· 2017
[cited by applicant]
US 9949936B2
· Guy et al.
· 2018
[cited by applicant]
US 9949937B2
· Guy et al.
· 2018
[cited by applicant]
US 9956183B2
· Guy et al.
· 2018
[cited by applicant]
US 9956184B2
· Guy et al.
· 2018
[cited by applicant]
US 9956185B2
· Guy et al.
· 2018
[cited by applicant]
US 9956186B2
· Guy et al.
· 2018
[cited by applicant]
US 9962341B2
· Stott et al.
· 2018
[cited by applicant]
US 20170239193A1
· Guy et al.
· 2017
[cited by applicant]
US 20180071210A1
· Wilkhu et al.
· 2018
[cited by applicant]
US 20190247333A1
· Farfel et al.
· 2019
[cited by applicant]
US 20200138738A1
· Guy et al.
· 2020
[cited by applicant]
US 20200179303A1
· Guy et al.
· 2020
[cited by applicant]
US 20200206153A1
· Whalley et al.
· 2020
[cited by applicant]
US 20200352878A1
· Guy et al.
· 2020
[cited by applicant]
US 20210052512A1
· Guy et al.
· 2021
[cited by applicant]
US 20210059949A1
· Wilkhu et al.
· 2021
[cited by applicant]
US 20210059976A1
· Wilkhu et al.
· 2021
[cited by applicant]
US 20210069333A1
· Velasco Diez et al.
· 2021
[cited by applicant]
US 20210169824A1
· Guy et al.
· 2021
[cited by applicant]
US 20210330636A1
· Guy et al.
· 2021
[cited by applicant]
US 20220008355A1
· Guy et al.
· 2022
[cited by applicant]
US 20220016048A1
· Guy et al.
· 2022
[cited by applicant]
US 20220023232A1
· Guy et al.
· 2022
[cited by applicant]
US 20220087951A1
· Knappertz
· 2022
[cited by applicant]
US 20220183997A1
· Guy et al.
· 2022
[cited by applicant]
US 20220184000A1
· Guy et al.
· 2022
[cited by applicant]
US 20220202738A1
· Guy et al.
· 2022
[cited by applicant]
US 20220211629A1
· Wilkhu et al.
· 2022
[cited by applicant]
US 20220226257A1
· Guy et al.
· 2022
[cited by applicant]
US 20220233495A1
· Silcock et al.
· 2022
[cited by applicant]
US 20220249396A1
· Guy et al.
· 2022
[cited by applicant]
US 20220257529A1
· Guy et al.
· 2022
[cited by applicant]
US 20220378714A1
· Guy et al.
· 2022
[cited by applicant]
US 20220378715A1
· Guy et al.
· 2022
[cited by applicant]
US 20220378738A1
· Guy et al.
· 2022
[cited by applicant]
US 20230032502A1
· Guy et al.
· 2023
[cited by applicant]
US 20230038423A1
· Silcock et al.
· 2023
[cited by applicant]
US 20230143812A1
· Knappertz et al.
· 2023
[cited by applicant]
US 20230277560A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230277561A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230277562A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230277563A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285419A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285420A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285421A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285422A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285423A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285424A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285428A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230310464A1
· Checketts et al.
· 2023
[cited by applicant]
GB 2531280A
· 2016
[cited by applicant]
WO WO2019045121A1
· 2019
[cited by applicant]
WO WO2019071302A1
· 2019
[cited by applicant]
WO WO2019207319A1
· 2019
[cited by applicant]
WO WO2020161083A1
· 2020
[cited by applicant]
Deacon, H., “The fight for getting access to medical cannabis in the UK goes on,” Aug. 23, 2019, 8 pages; https://www.healtheuropa.eu/access-to-medical-cannabis-in-the-uk/93025/.
[cited by applicant]
Devinsky, O. et al., “Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial,” The Lancet Neurology, Published online; Dec. 23, 2015; 9 pages; doi:https://doi.org/10.1016/S1474-442…
[cited by applicant]
Devinsky, O. et al., “Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome,” N Engl J Med, 376(21):2011-2020 (2017).
[cited by applicant]
Eadie, M. J., “Shortcomings in the current treatment of epilepsy,” Expert Rev Neurother., 12(12):1419-1427 (2012).
[cited by applicant]
Elsohly, M. & Gul, W., Handbook of Cannabis, Chapter 1, Constituents of Cannabis Sativa, Roger Pertwee, Ed., 2012, 21 pages.
[cited by applicant]
EPIDIOLEX® (cannabidiol) oral solution, CV, Prescribing Information, 2018, 30 pages; https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf.
[cited by applicant]
Hausman-Kedem, M. et al., “Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents—An observational, longitudinal study,” Brain Dev., 40(7):544-551 (2018); doi:10.1016/…
[cited by applicant]
Hess, E. J. et al., “Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex,” Epilepsia, 57(10):1617-1624 (2016); doi:10.1111/epi.13499.
[cited by applicant]
Kurian, M. et al., “Focal cortical malformations in children with early infantile epilepsy and PCDH19 mutations: case report,” Developmental Medicine & Child Neurology, 60(1):100-105 (2018); doi: 10.1111/dmcn.13595. Epu…
[cited by applicant]
Kwan, P. et al., “Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies,” Epilepsia, 51(6):1069-1077; doi:10.1111/j.1528-1167.2009.02397.x. E…
[cited by applicant]
Oppenheim, M., “Government refuses medical cannabis to six-year-old epileptic boy who had 3,000 seizures in a year,” Feb. 18, 2018, 6 pages; https://www.independent.co.uk/news/uk/home-news/alfie-dingley-home-office-medi…
[cited by applicant]
Pertwee, R. G., “The Pharmacology and Therapeutic Potential of Cannabidiol,” Cannabinoids, Chapter 3, DiMarzo, V. (Ed.), pp. 32-83 (2004).
[cited by applicant]
Porter, B. E. & Jacobson, C., “Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy,” Epilepsy Behav., 29(3):574-577 (2013).
[cited by applicant]
Rosenberg, E. C. et al., “Quality of Life of Childhood Epilepsy (QOLCE) in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol (CBD),” Epilepsia, 58(8):e96-e100 (2017); doi:10.1111/e…
[cited by applicant]
Thiele, E. et al., “Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study,” Epilepsia, 60:419-428 (2019).
[cited by applicant]
Thurman, D. J. et al., “Standards for epidemiologic studies and surveillance of epilepsy,” Epilepsia, 52 (Suppl 7):2-26 (2011).
[cited by applicant]
U.S. Appl. No. 15/640,033, filed Jun. 30, 2017.
[cited by applicant]
U.S. Appl. No. 16/768,241, filed May 29, 2020.
[cited by applicant]
U.S. Appl. No. 16/959,350, filed Jun. 30, 2020.
[cited by applicant]
U.S. Appl. No. 16/959,354, filed Jun. 30, 2020.
[cited by applicant]
U.S. Appl. No. 16/959,357, filed Jun. 30, 2020.
[cited by applicant]
U.S. Appl. No. 16/935,005, filed Jul. 21, 2020.
[cited by applicant]
U.S. Appl. No. 17/012,448, filed Sep. 4, 2020.
[cited by applicant]
U.S. Appl. No. 17/050,956, filed Oct. 27, 2020.
[cited by applicant]
U.S. Appl. No. 17/102,109, filed Nov. 23, 2020.
[cited by applicant]
U.S. Appl. No. 17/231,625, filed Apr. 15, 2021.
[cited by applicant]
U.S. Appl. No. 17/296,066, filed May 21, 2021.
[cited by applicant]
U.S. Appl. No. 17/296,076, filed May 21, 2021.
[cited by applicant]
U.S. Appl. No. 17/424,682, filed Jul. 21, 2021.
[cited by applicant]
U.S. Appl. No. 17/426,442, filed Jul. 28, 2021.
[cited by applicant]
U.S. Appl. No. 17/406,401, filed Aug. 19, 2021.
[cited by applicant]
U.S. Appl. No. 17/435,892, filed Sep. 2, 2021.
[cited by applicant]
U.S. Appl. No. 17/472,000, filed Sep. 10, 2021.
[cited by applicant]
U.S. Appl. No. 17/548,232, filed Dec. 10, 2021.
[cited by applicant]
U.S. Appl. No. 17/606,370, filed Oct. 25, 2021.
[cited by applicant]
U.S. Appl. No. 17/611,824, filed Nov. 16, 2021.
[cited by applicant]
U.S. Appl. No. 17/529,005, filed Nov. 17, 2021.
[cited by applicant]
U.S. Appl. No. 17/552,487, filed Dec. 16, 2021.
[cited by applicant]
U.S. Appl. No. 17/576,868, filed Jan. 14, 2022.
[cited by applicant]
U.S. Appl. No. 17/585,485, filed Jan. 26, 2022.
[cited by applicant]
U.S. Appl. No. 17/627,946, filed Jan. 18, 2022.
[cited by applicant]
U.S. Appl. No. 17/631,069, filed Jan. 28, 2022.
[cited by applicant]
U.S. Appl. No. 17/638,629, filed Feb. 25, 2022.
[cited by applicant]
U.S. Appl. No. 17/689,607, filed Mar. 8, 2022.
[cited by applicant]
U.S. Appl. No. 17/689,245, filed Mar. 8, 2022.
[cited by applicant]
U.S. Appl. No. 17/744,224, filed May 13, 2022.
[cited by applicant]
U.S. Appl. No. 17/705,443, filed Mar. 28, 2022.
[cited by applicant]
U.S. Appl. No. 17/768,048, filed Apr. 11, 2022.
[cited by applicant]
U.S. Appl. No. 17/770,435, filed Apr. 20, 2022.
[cited by applicant]
U.S. Appl. No. 17/770,436, filed Apr. 20, 2022.
[cited by applicant]
U.S. Appl. No. 17/771,184, filed Apr. 22, 2022.
[cited by applicant]
U.S. Appl. No. 17/771,190, filed Apr. 22, 2022.
[cited by applicant]
U.S. Appl. No. 17/771,195, filed Apr. 22, 2022.
[cited by applicant]
U.S. Appl. No. 17/771,183, filed Apr. 22, 2022.
[cited by applicant]
U.S. Appl. No. 17/777,734, filed May 18, 2022.
[cited by applicant]
U.S. Appl. No. 17/777,677, filed May 18, 2022.
[cited by applicant]
U.S. Appl. No. 17/777,681, filed May 18, 2022.
[cited by applicant]
U.S. Appl. No. 17/841,167, filed Jun. 15, 2022.
[cited by applicant]
U.S. Appl. No. 17/786,949, filed Jun. 17, 2022.
[cited by applicant]
U.S. Appl. No. 17/817,753, filed Aug. 5, 2022.
[cited by applicant]
U.S. Appl. No. 17/853,367, filed Jun. 29, 2022.
[cited by applicant]
U.S. Appl. No. 18/002,437, filed Dec. 19, 2022.
[cited by applicant]
U.S. Appl. No. 18/005,838, filed Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,841, filed Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,845, filed Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,843, filed Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,847, filed Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,848, filed Jan. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,851, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,852, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,853, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,959, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,960, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/005,961, filed Jan. 18, 2023.
[cited by applicant]
U.S. Appl. No. 18/006,125, filed Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/006,127, filed Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/006,129, filed Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/006,131, filed Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/006,133, filed Jan. 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/161,603, filed Jan. 30, 2023.
[cited by applicant]
U.S. Appl. No. 18/170,235, filed Feb. 16, 2023.
[cited by applicant]
U.S. Appl. No. 18/043,810, filed Mar. 2, 2023.
[cited by applicant]
U.S. Appl. No. 18/044,941, filed Mar. 10, 2023.
[cited by applicant]
U.S. Appl. No. 18/245,856, filed Mar. 17, 2023.
[cited by applicant]
U.S. Appl. No. 18/186,792, filed Mar. 20, 2023.
[cited by applicant]
U.S. Appl. No. 18/311,221, filed May 2, 2023.
[cited by applicant]
U.S. Appl. No. 18/320,906, filed May 19, 2023.
[cited by applicant]
U.S. Appl. No. 18/256,307, filed Jun. 7, 2023.
[cited by applicant]
U.S. Appl. No. 18/257,373, filed Jun. 14, 2023.
[cited by applicant]
U.S. Appl. No. 18/257,537, filed Jun. 14, 2023.
[cited by applicant]
U.S. Appl. No. 18/257,479, filed Jun. 14, 2023.
[cited by applicant]
U.S. Appl. No. 18/258,485, filed Jun. 20, 2023.
[cited by applicant]
U.S. Appl. No. 18/446,405, filed Aug. 8, 2023.
[cited by applicant]
U.S. Appl. No. 18/546,254, filed Aug. 11, 2023.
[cited by applicant]
U.S. Appl. No. 18/548,003, filed Aug. 25, 2023.
[cited by applicant]
U.S. Appl. No. 18/477,467, filed Sep. 28, 2023.
[cited by applicant]
U.S. Appl. No. 18/479,671, filed Oct. 2, 2023.
[cited by applicant]
U.S. Appl. No. 18/560,316, filed Nov. 10, 2023.
[cited by applicant]
U.S. Appl. No. 18/560,337, filed Nov. 10, 2023.
[cited by applicant]
U.S. Appl. No. 18/560,341, filed Nov. 10, 2023.
[cited by applicant]
U.S. Appl. No. 18/560,346, filed Nov. 10, 2023.
[cited by applicant]
Chiron, C. & Dulac, O., “The pharmacologic treatment of Dravet syndrome,” Epilepsia, 52(Suppl 2):72-5 (Apr. 2011).
[cited by applicant]
Dulac, O. & Kaminska, A., “Use of Lamotrigine in Lennox-Gastaut and Related Epilepsy Syndromes,” J. Child Neurolog., 12(Suppl 1): S23-S29 (Nov. 1997).
[cited by applicant]
Kelley, S. A. & Kossoff, E. H., “Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress,” Developmental Med. & Child Neurol., 52(11):988-93 (Nov. 2010).
[cited by applicant]
Lutz, B., “On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures.” Biochemical Pharmacology 68: 1691-1698 (Nov. 2004).
[cited by applicant]
Mayo Clinic, “Carbamazepine (oral route),” [drug information], provided by Merative, Micromedex®, DRG-20062739, (initial publication date unknown; last updated Feb. 1, 2026). [Accessed Feb. 12, 2026, publicly available …
[cited by applicant]
Mayo Clinic, “Phenytoin (oral route),” [drug information], provided by Merative, Micromedex®, DRG-20072875, (initial publication date unknown; last updated Feb. 1, 2026). [Accessed Feb. 12, 2026, publicly available at U…
[cited by applicant]
Mayo Clinic, “Vigabatrin (oral route),” [drug information], provided by Merative, Micromedex®, DRG-20066675, (initial publication date unknown, last updated Feb. 1, 2026). [Accessed Mar. 2, 2026, publicly available at U…
[cited by applicant]
U.S. Food and Drug Administration, “What We Do,” [website] FDA.gov., U.S. Department of Health and Human Services, (initial publication unknown; last updated Nov. 21, 2023). [Accessed Feb. 12, 2026, publicly available a…
[cited by applicant]
Vossler, D. G. & Gidal, B. E., “A summary of antiseizure medications available in the United States: 4th Edition,” American Epilepsy Society, (Revised Apr. 1, 2024), 28 pages.
[cited by applicant]